<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Neurol. Sci</journal-id><journal-title-group><journal-title>Neurological Sciences</journal-title></journal-title-group><issn pub-type="ppub">1590-1874</issn><issn pub-type="epub">1590-3478</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7200170</article-id><article-id pub-id-type="publisher-id">4444</article-id><article-id pub-id-type="doi">10.1007/s10072-020-04444-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>New challenges from Covid-19 pandemic: an unexpected opportunity to enlighten the link between viral infections and brain disorders?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7388-4463</contrib-id><name><surname>Gialluisi</surname><given-names>Alessandro</given-names></name><address><email>alessandro.gialluisi@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>de Gaetano</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Iacoviello</surname><given-names>Licia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.419543.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1760 3561</institution-id><institution>Department of Epidemiology and Prevention, </institution><institution>IRCCS NEUROMED, </institution></institution-wrap>Via dell&#x02019;Elettronica, 86077 Pozzilli, Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.18147.3b</institution-id><institution-id institution-id-type="ISNI">0000000121724807</institution-id><institution>Research Center in Epidemiology and Preventive Medicine (EPIMED), Department of Medicine and Surgery, </institution><institution>University of Insubria, </institution></institution-wrap>Varese, Italy </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>5</month><year>2020</year></pub-date><fpage>1</fpage><lpage>2</lpage><history><date date-type="received"><day>7</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Fondazione Societ&#x000e0; Italiana di Neurologia 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004710</institution-id><institution>Fondazione Umberto Veronesi</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body><p id="Par1">Dear Editor,</p><p id="Par2">We read with great interest recent reports of sensorial impairments in Covid-19 patients, both in the early [<xref ref-type="bibr" rid="CR1">1</xref>] and in a later phase of the infection [<xref ref-type="bibr" rid="CR2">2</xref>]. It is time for the scientific community to consider potential challenges and opportunities of the Covid-19 pandemic beyond clinical emergency, based on these and other observations. Among these, neurological consequences of the disease may represent an unexpected feature of translational relevance.</p><p id="Par3">Indeed, infectious diseases have been associated with an increased risk of neurodegenerative and neuropsychiatric disorders [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. While this link may look obvious for multiple sclerosis, due to its auto-immune nature [<xref ref-type="bibr" rid="CR5">5</xref>], it is less so for disorders due to the accumulation of neurotoxic aggregates, like Parkinson&#x02019;s and Alzheimer&#x02019;s disease. Influenza epidemics are associated with neurological manifestations, and the H<sub>5</sub>N<sub>1</sub> virus reportedly induces Parkinsonian pathology in mice, both findings possibly explained by the activation of inflammatory pathways [<xref ref-type="bibr" rid="CR4">4</xref>]. However, the exact mechanisms of these effects and whether coronaviruses show a similar action remain unclear. The current Covid-19 pandemic provides an unprecedented opportunity to disentangle the link between viral/infectious diseases, inflammation, and the risk of brain disorders, as mentioned here below.</p><p id="Par4">Many Covid-19 patients present with loss of taste and olfaction [<xref ref-type="bibr" rid="CR1">1</xref>], even after the acute phase of infection [<xref ref-type="bibr" rid="CR2">2</xref>]. Hyposmia is a common symptom of different neurodegenerative and neuropsychiatric disorders [<xref ref-type="bibr" rid="CR6">6</xref>] and has been associated with levels of interleukin-6 (IL-6), an inflammatory biomarker deeply investigated in brain disorders [<xref ref-type="bibr" rid="CR7">7</xref>]. Of note, IL-6 action is blocked by tocilizumab, a drug currently used to inhibit cytokine storm in Covid-19 patients [<xref ref-type="bibr" rid="CR8">8</xref>]. A recent study revealed c-reactive protein levels above the low-grade inflammation threshold (&#x0003e;&#x02009;3&#x000a0;mg/l) for three out of four patients presenting with loss of taste and olfaction, which were reported to be more intense and long-lasting than those in common cold disease [<xref ref-type="bibr" rid="CR2">2</xref>]. Therefore, accumulating evidence suggests systemic inflammation may be a potential pathway to explain neurological sequelae of Covid-19, a hypothesis which should be investigated more in depth.</p><p id="Par5">About half of hospitalized patients are &#x0003e;&#x02009;55&#x000a0;years [<xref ref-type="bibr" rid="CR9">9</xref>]: the resulting higher age-related risk of neurodegenerative disorders is a good setting to investigate triggering and double-hit mechanisms previously hypothesized for viral infections [<xref ref-type="bibr" rid="CR4">4</xref>]. The high diffusion of Covid-19 (1,873,265 ascertained cases worldwide as of April 14, 2020; <ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases">https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases</ext-link>) ensures a high power to detect effects on the incident risk of brain disorders. Indeed, the rapid spread of the infection through different ethnicities and cultural and genetic backgrounds may allow planning robust multicenter studies.</p><p id="Par6">To sum up, the current Covid-19 pandemic provides an extraordinary window to implement a worldwide collaborative effort, aimed at enlightening the largely unexplored relationship between viral infections, inflammation, and brain disorders. To this purpose, coordination of hospitals and general practice and public health institutions will be needed to collect, store, and allow access to electronic health records during and after the epidemic. We &#x0201c;call to arms&#x0201d; clinicians and researchers worldwide, to take an unexpected advantage from a painful event and make it an extraordinary opportunity to fight brain disorders, which represent a huge challenge and a heavy burden for national health systems.</p></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding information</title><p>AG was supported by Fondazione Umberto Veronesi.</p></notes><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes notes-type="COI-statement"><title>Conflict of interest</title><p id="Par7">The authors declare that they have no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Giacomelli A, Laura P, Conti F et al (2020) Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study | clinical infectious diseases | Oxford Academic. Clin Infect Dis. 10.1093/cid/ciaa330</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">W&#x000f6;lfel R, Corman VM, Guggemos W et al (2020) Virological assessment of hospitalized patients with COVID-2019. Nature:1&#x02013;10. 10.1038/s41586-020-2196-x</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Bullido MJ, Carter C, Clerici M, et al (2017) Microbes and Alzheimer&#x02019;s disease 51:979&#x02013;984. 10.3233/JAD-160152.Microbes</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>J</given-names></name><name><surname>Smeyne</surname><given-names>RJ</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>B</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name></person-group><article-title>Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries</article-title><source>Parkinsonism Relat Disord</source><year>2010</year><volume>16</volume><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2010.06.012</pub-id><?supplied-pmid 20650672?><pub-id pub-id-type="pmid">20650672</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fierz</surname><given-names>W</given-names></name></person-group><article-title>Multiple sclerosis: an example of pathogenic viral interaction?</article-title><source>Virol J</source><year>2017</year><volume>14</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s12985-017-0719-3</pub-id><pub-id pub-id-type="pmid">28241767</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turetsky</surname><given-names>BI</given-names></name><name><surname>Hahn</surname><given-names>CG</given-names></name><name><surname>Borgmann-Winter</surname><given-names>K</given-names></name><name><surname>Moberg</surname><given-names>PJ</given-names></name></person-group><article-title>Scents and nonsense: olfactory dysfunction in schizophrenia</article-title><source>Schizophr Bull</source><year>2009</year><volume>35</volume><fpage>1117</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbp111</pub-id><?supplied-pmid 19793796?><pub-id pub-id-type="pmid">19793796</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henkin</surname><given-names>RI</given-names></name><name><surname>Schmidt</surname><given-names>L</given-names></name><name><surname>Velicu</surname><given-names>I</given-names></name></person-group><article-title>Interleukin 6 in hyposmia</article-title><source>JAMA Otolaryngol Neck Surg</source><year>2013</year><volume>139</volume><fpage>728</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1001/jamaoto.2013.3392</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><etal/></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet.</source><year>2020</year><volume>395</volume><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id><?supplied-pmid 32192578?><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bialek</surname><given-names>S</given-names></name><name><surname>Boundy</surname><given-names>E</given-names></name><name><surname>Bowen</surname><given-names>V</given-names></name><etal/></person-group><article-title>Severe outcomes among patients with coronavirus disease 2019 (COVID-19) &#x02014; United States, February 12&#x02013;March 16, 2020</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2020</year><volume>69</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6912e2</pub-id><pub-id pub-id-type="pmid">32214079</pub-id></element-citation></ref></ref-list></back></article>